Bullish
Allergan Aesthetics has released "What Consumers Really Want," the latest in its "The Aesthetics Evolution" series, exploring current consumer motivat...
AbbVie (ABBV) is strategically focusing on immunology, oncology, neuroscience, and aesthetics, with obesity identified as a new area for growth. The c...
Neutral
This article highlights seven healthcare stocks that have triggered "whale alerts" due to significant options trading activity. These alerts, tracked ...
Bullish
The Inflammatory Bowel Disease (IBD) market is projected to see significant growth by 2036, driven by an expanding pipeline of treatments and increasi...
AbbVie stock has shown independence from the broader market, with a low correlation to the S&P 500 and outperforming returns. Its strength is attribut...
AbbVie (NYSE: ABBV) is set to present extensive new data from its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress, i...
Bullish
AbbVie (ABBV) stock has a TIKR model price target of $350 by December 2030, representing a 54% upside from its current price of $227, or approximately...
Bearish
AbbVie lost its latest legal challenge against a Mississippi law that regulates how drug companies contract with pharmacies under the federal drug dis...
Bullish
Aldeyra Therapeutics (ALDX) is nearing a crucial FDA decision for its late-stage dry eye disease program, which involves imminent regulatory hurdles a...
Bullish
A British drug-cost watchdog has recommended the use of AbbVie's ovarian cancer therapy. The news was reported by Refinitiv and is a significant devel...
Neutral
Vantus Wealth LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, according to its most recent 13F filing with th...
Neutral
AbbVie (NYSE: ABBV) is scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Management will host a ...
Bullish
AbbVie Inc. (NYSE:ABBV) recently received FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) to treat blastic plasmacytoid dendritic cell neoplasm (B...
Neutral
AbbVie (NYSE: ABBV) will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference. Management plans to hold a fireside chat on T...
Neutral
AbbVie (ABBV) recently received European Commission approval to expand the label for its drug Venclyxto, allowing its use with acalabrutinib and ibrut...
Neutral
AbbVie Inc. (NYSE: ABBV) has received European Commission authorization to expand the label for its cancer drug VENCLYXTO. This approval allows for ne...
Bullish
The European Commission has authorized an expanded label for AbbVie's VENCLYXTO (venetoclax) in previously untreated adult chronic lymphocytic leukemi...
Bullish
Ironwood Pharmaceuticals and AbbVie have received FDA approval for a label expansion of their bowel disorder therapy, Linzess. The drug is now indicat...
Bullish
In CNBC's "Final Trades," analysts discussed their picks: AbbVie (ABBV), Deckers Outdoor (DECK), and Goldman Sachs (GS). AbbVie recently received a po...
Bullish
Piper Sandler has increased its price target for AbbVie Inc. (ABBV) to $298 from $294, maintaining an Overweight rating, citing the company's robust i...